Abiopharma

🔍 TRAVERS DAVID (Executive)

Company: ZIPRECRUITER, INC. (ZIP)

Report Date: 2026-03-15

Detailed Transactions and Holdings:

• Acquired 13,347 shares of Class A Common Stock (Direct)
  Date: 2026-03-15 | Code: M | equity_swap_involved: 0 | shares_owned_after: 1,246,012.00 | transaction_form_type: 4
• Acquired 20,691 shares of Class A Common Stock (Direct)
  Date: 2026-03-15 | Code: M | equity_swap_involved: 0 | shares_owned_after: 1,266,703.00 | transaction_form_type: 4
• Acquired 20,444 shares of Class A Common Stock (Direct)
  Date: 2026-03-15 | Code: M | equity_swap_involved: 0 | shares_owned_after: 1,287,147.00 | transaction_form_type: 4
• Acquired 14,238 shares of Class A Common Stock (Direct)
  Date: 2026-03-15 | Code: M | equity_swap_involved: 0 | shares_owned_after: 1,301,385.00 | transaction_form_type: 4
• Sold 38,422 shares of Class A Common Stock at $2.83 per share (Direct)
  Date: 2026-03-15 | Code: F | equity_swap_involved: 0 | shares_owned_after: 1,262,963.00 | transaction_form_type: 4 | Footnotes: F1
• Sold 13,347 shares of Restricted Stock Units (Derivative)
  Date: 2026-03-15 | Code: M | equity_swap_involved: 0 | shares_owned_after: 40,039.00 | transaction_form_type: 4 | Footnotes: F2, F2, F3, F4
• Sold 20,691 shares of Restricted Stock Units (Derivative)
  Date: 2026-03-15 | Code: M | equity_swap_involved: 0 | shares_owned_after: 144,831.00 | transaction_form_type: 4 | Footnotes: F2, F2, F5, F4
• Sold 20,444 shares of Restricted Stock Units (Derivative)
  Date: 2026-03-15 | Code: M | equity_swap_involved: 0 | shares_owned_after: 224,880.00 | transaction_form_type: 4 | Footnotes: F2, F2, F6, F4
• Sold 14,238 shares of Restricted Stock Units (Derivative)
  Date: 2026-03-15 | Code: M | equity_swap_involved: 0 | shares_owned_after: 213,562.00 | transaction_form_type: 4 | Footnotes: F2, F2, F7, F4

Footnotes:

• F1: Exempt transaction pursuant to Section 16b-3(e) - payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3. All of the shares reported as disposed of in this Form 4 were relinquished by the Reporting Person and cancelled by the Issuer in exchange for the Issuer's agreement to pay federal and state tax withholding obligations of the Reporting Person resulting from the vesting of restricted stock units (the "RSUs"). The Reporting Person did not sell or otherwise dispose of any of the shares reported on this Form 4 for any reason other than to cover required taxes.
• F2: Each RSU represents a contingent right to receive one share of the Issuer's Class A Common Stock upon settlement.
• F3: The RSUs vest and are scheduled to settle as to 1/16 of the total shares quarterly beginning on March 15, 2023 until fully vested, subject to the Reporting Person's continued service to the Issuer on each vesting date.
• F4: RSUs do not expire; they either vest or are canceled prior to vesting date.
• F5: The RSUs vest as to 1/16 of the total shares quarterly beginning on March 15, 2024 until fully vested, subject to the Reporting Person's continued service to the Issuer on each vesting date.
• F6: The RSUs vest as to 1/16 of the total shares quarterly beginning on March 15, 2025 until fully vested, subject to the Reporting Person's continued service to the Issuer on each vesting date.
• F7: The RSUs vest as to 1/16 of the total shares quarterly beginning on March 15, 2026 until fully vested, subject to the Reporting Person's continued service to the Issuer on each vesting date.
• REMARKS: Exhibit 24 - Power of Attorney